PubRank

Ron Bose

Author PubWeight™ 38.35‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012 8.03
2 Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012 6.09
3 Human Proteinpedia enables sharing of human protein data. Nat Biotechnol 2008 4.21
4 Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 2013 3.85
5 Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure 2008 2.79
6 Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 2007 2.78
7 DGIdb: mining the druggable genome. Nat Methods 2013 2.26
8 Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system. J Biol Chem 2009 1.36
9 Exome sequencing and cis-regulatory mapping identify mutations in MAK, a gene encoding a regulator of ciliary length, as a cause of retinitis pigmentosa. Am J Hum Genet 2011 1.16
10 Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers. Mol Cell Proteomics 2012 1.10
11 Using multigene tests to select treatment for early-stage breast cancer. J Natl Compr Canc Netw 2013 0.93
12 Carboxyl-group footprinting maps the dimerization interface and phosphorylation-induced conformational changes of a membrane-associated tyrosine kinase. Mol Cell Proteomics 2011 0.91
13 Identification of targets of c-Src tyrosine kinase by chemical complementation and phosphoproteomics. Mol Cell Proteomics 2012 0.90
14 Prioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing Data. PLoS One 2013 0.86
15 Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface. J Biol Chem 2013 0.85
16 Incorporating genomics into breast cancer clinical trials and care. Clin Cancer Res 2013 0.85
17 Tissue phosphoproteomics with PolyMAC identifies potential therapeutic targets in a transgenic mouse model of HER2 positive breast cancer. Electrophoresis 2014 0.78